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Available online 18 September 2014This is an old issue which should have been laid to rest
many years ago, but I feel bound to respond to the letter by Drs
Peckham and Whitaker replying to Professor Taylor (July 2014)
on the subject of Fibrosing Colonopathy (FC).
It remains important because younger clinicians may still
believe that enzymes which do not contain Eudragit are safer than
those which do. The studies which made this claim were carried
out by an industry-funded pathologist described by Prof Taylor as
“discredited”. That is an understatement. An official enquiry in
2001, which did not take into account his FC history, found him
guilty of, inter alia, “falsifying records, statistics and work output;
falsifying research applications; falsifying post mortem reports;
falsely representing that diagnoses and research papers were
supported by histological examination, when no histology had
been carried out; lying to parents; encouraging staff to falsify
records and statistics; practising deceit upon (the sponsors of
his post), the University and (the hospital); and taking with
him, after his dismissal, complete medical records”.1 As chairman
of the UK enquiry into FC, I would add that he removed or
destroyed all the histological material on which the conclusions of
our enquiry were based. He fraudulently added the names of two
senior pathologists to a report he sent to the Medicines Control
Agency, although they had not seen the report or most of the
material. He had refused to examine the slides together. HeE-mail address: j.a.dodge@btinternet.com.
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reporting the histology, and excluded at least 5 patients who
had only been taking Eudragit-free enzyme products from his
final series, sometimes reversing his documented diagnosis
of FC. He was determined to “prove” his Eudragit hypothesis
regardless of evidence.
Secondly, it is not correct that cases of FC disappeared from
the UK after 1955 “in contrast to the US”, quoting a 2001
poster presentation which followed a specific search for US
cases of FC between 1995 and 1999. No such search has been
carried out in the UK. It should be remembered that clinicians
may be reluctant to report cases of FC for fear of possible
litigation. I know of at least one proven British CF patient
whose surgical case report was submitted to this Journal in
2006, but not published. I handled the paper as a member of the
Editorial Board. The only enzyme product that patient ever took
did not include Eudragit.
It is time that we in the UK should accept once and for
all that it is enzymes which cause this usually iatrogenic
disease. The North American enquiry confirmed that nearly
20 years ago. I submit that there should be no lingering
doubts about the relative safety of one product versus another:
high doses of enzymes may be harmful, regardless of the
formulation.ll rights reserved.
